Clinical trials
Lupus or SLE clinical trials
Below are recruiting lupus or sle clinical trials, each written for real people, not researchers. We’re tracking 333 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07323524RecruitingPhase 4
Dapagliflozin for active lupus kidney disease
This study tests if a diabetes drug called dapagliflozin can help people with active lupus nephritis by reducing protein in the urine and preserving kidney function. It is given in addition to standard treatments.
Boston, MassachusettsAges 18–70 - NCT05927688Recruiting
Using patient reports to adjust treatment for autoimmune diseases
This study looks at whether doctors consider patient “electronic reports” (completed online/phone) when deciding how often to change treatment. It may help improve how well treatment plans match how patients feel over time.
StrasbourgAges 18 years+ - NCT07313475Recruiting
Testing a new tool to detect lupus anticoagulant
This trial checks if a new method (Cryocheck HexLA Integrated TCA) can accurately find lupus anticoagulant in blood samples. Your leftover blood from regular tests may be used, and it requires no extra visits.
StrasbourgAges 18 years+ - NCT07299422RecruitingPhase 2
Study of SHR-2173 for people with lupus
This trial tests a new drug called SHR-2173 for people with active lupus. It aims to see if it can reduce disease activity when taken with standard treatments.
Beijing, Beijing MunicipalityAges 18–65 - NCT07302113Recruiting
Online thinking skills program for teens with lupus
This study tests a virtual (online) program to help teens with lupus improve thinking and daily life skills. It is designed for youth ages 13–18 with childhood-onset lupus.
Toronto, OntarioAges 13–18 - NCT07282392Recruiting
Emotional awareness therapy for lupus and fibromyalgia pain
This study tests if a therapy called Emotional Awareness and Expression Therapy (EAET) can help people with lupus and fibromyalgia or chronic widespread pain feel better by addressing emotional factors that may worsen their pain. You would attend sessions to learn how to understand and express your emotions in healthy ways.
Salt Lake City, UtahAges 18–65 - NCT06261021RecruitingPhase 2
Ruxolitinib cream for discoid lupus study
This trial tests a cream (ruxolitinib) on discoid lupus skin lesions. It aims to see if the cream can reduce DLE symptoms in adults.
Fredericton, New BrunswickAges 18 years+ - NCT06349343RecruitingPhase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
WuhanAges 18–70 - NCT07260942Recruiting
Study of ferroptosis in lupus
This study looks at whether a type of cell death called ferroptosis plays a role in lupus. Participants with lupus or with rheumatoid arthritis or inflammatory bowel disease will be compared to understand more about how lupus works.
BordeauxAges 18 years+ - NCT06365359Recruiting
Lupus and pesticide exposure in Martinique
This study looks at how exposure to a pesticide called chlordecone might affect people with lupus in Martinique. Researchers want to understand if there is a link between the chemical and lupus symptoms or kidney problems.
Fort-de-FranceAges 18 years+ - NCT06904729RecruitingPhase 3
CAR-T cell therapy for tough lupus kidney disease in children
This trial tests a new type of immune cell therapy (CAR-T cells) for children whose lupus kidney disease (lupus nephritis) has not responded to standard treatments. The CAR-T cells are designed to target and remove certain immune cells that are attacking the kidneys, with the goal of stopping the disease.
Guangzhou, GuangdongAges 6–18 - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT07225387RecruitingPhase 4
Belimumab and voclosporin for lupus kidney disease
This study tests whether combining two medications, belimumab and voclosporin, is safe and effective for treating a specific type of lupus that affects the kidneys (lupus nephritis). It may help people with active kidney inflammation who need better control of their disease.
Glendale, ArizonaAges 18–80 - NCT07229742RecruitingPhase 2
Study of SHR-2173 for active lupus nephritis
This trial tests a new medicine called SHR-2173 for people with active lupus nephritis, a kidney inflammation caused by lupus. The goal is to see if it is safe and effective.
Nanjing, JiangsuAges 18–70 - NCT05018858RecruitingPhase 1
Test stem cell infusion safety for lupus
This early-phase study tests whether an intravenous (through a vein) stem cell treatment made from donated umbilical cord tissue is safe for people with lupus. It focuses mainly on side effects and how well participants tolerate the infusion.
St John'sAges Any age - NCT06920433RecruitingEarly Phase 1
Targeted cell therapy for tough lupus with kidney involvement
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07136389RecruitingPhase 1
Testing 2 drugs for active lupus skin disease
This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.
Saint PetersburgAges 18–70 - NCT07038447Enrolling by invitationPhase 1
A study of KITE-363 for people with severe autoimmune diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune diseases (like lupus, scleroderma, or inflammatory myositis) that haven't improved with standard treatments. The goal is to see if KITE-363 can reduce disease activity and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT07043153Recruiting
Predicting lupus disease activity with blood tests
This study looks at whether two blood markers (AGR and PNI) can help track how active lupus is. You may be eligible if you have lupus and are not pregnant or have other serious health conditions.
SohagAges 18 years+ - NCT07017868Recruiting
Uric acid and other blood markers in lupus kidney disease
This study looks at whether certain substances in the blood, such as uric acid, homocysteine, and interleukin-17, are higher in people with lupus-related kidney disease compared to healthy individuals. It aims to find new ways to monitor or understand the condition better.
SohagAges 18 years+ - NCT06340750RecruitingPhase 1
BAFF CAR-T cells for lupus that hasn't improved with standard treatments
This trial tests a new type of cell therapy called BAFF CAR-T cells (LMY-920) for lupus that hasn't gotten better with standard treatments. It aims to see if these special immune cells can help calm the overactive immune system in lupus.
Columbus, OhioAges 18–65 - NCT06975787RecruitingPhase 1
A New Bispecific Antibody for Lupus Nephritis
This trial is testing a new type of medicine called a 'bispecific antibody' for people whose lupus nephritis has not responded to standard treatments or keeps coming back. The goal is to find a safe dose that might better control the kidney inflammation.
San Francisco, CaliforniaAges 18–60 - NCT06916806RecruitingPhase 1
Study of AZD5492 for lupus, myositis, or rheumatoid arthritis
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
Anniston, AlabamaAges 18–70 - NCT06921239Recruiting
HLA antibodies in lupus patients
This study looks for certain immune markers (HLA antibodies) in stored blood samples from people with lupus. It may help doctors understand how the immune system behaves in lupus.
AmiensAges 18 years+
Hear when a new Lupus or SLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus or sle?
- Yes. Clin2 currently lists 333 recruiting lupus or sle studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus or sle trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus or sle trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.